Over the past decade, knowledge about the pathogenesis of human tumors has been attributed to andlimited by the availability of well-characterized human tissues and fluids. With this in mind, tissue/biologicfluid facilities have emerged as a means of overseeing specimen collection, storage, processing anddistribution for investigative studies. The purpose of the Specimen Resource is to provide human tissues,biologic fluids and expert pathologic interpretation to SPORE investigators; and to maintain a large anddiverse specimen bank for future studies. The Specimen Resource will collect tissues/biologic fluids in amanner that meets the needs of the individual investigators without compromising clinical patient care; storethese samples in such a way as to ensure long-term security and easy accessibility; process samples so thatthey are suitable for further analysis; and distribute samples to investigators in a timely fashion. To maximizetranslational impact of the projects, specimens are collected and processed under the supervision ofpathologists in close collaboration with a multidisciplinary team of clinical specialists and basic researchinvestigators with a common expertise in neoplasia of the upper respiratory tract. A concerted effort tocollect and bank tissue specimens and biologic fluids from the upper respiratory tract has been an ongoingeffort since 1990. These materials have been collected with appropriate IRB approval and patient consent.The specimens are primarily obtained from patients with head and neck squamous cell carcinoma or frompatients at risk of developing this tumor. The fresh frozen specimen bank currently houses 26,092specimens from 5,147 patients including 3,381 carcinomas,4,838 phenotypically normal tissues includingmucosa taken from the surgical margins of cancer resections,4,691 oral rinses/swabs, 3,831 plasmasamples, 5,352 serum samples, and 166fine needle aspirates. These samples are cataloged in a state ofthe art database (i.e. HAND database) and efficiently stored for efficient retrieval. In many cases, thesamples have already been processed (e.g.microdissected for enrichment of tumor DMA) and are availablein the form of extracted DMA, RNA and/or protein. The Specimen Resource is staffed by pathologists withexpertise in neoplasia of the upper respiratory tract, and has ready access to a laser capture microdissectionfacility, a tissue array facility, an immunohistochemistry facility, and an in-situ hybridization facility.
Showing the most recent 10 out of 137 publications
